Inevitably, this is dependent on the elucidation of the details of aberrant PI3K signaling in the different breast cancer subtypes and resistance mechanisms in response to PI3K inhibition and to previous or concurrent treatment. The gene discussed is PIK3CB; the disease is breast cancer.